Navigation Links
Statement of America's Specialty Medicines Companies On House Health Care Bill (H.R. 3962)

WASHINGTON, Nov. 6 /PRNewswire-USNewswire/ -- America's Specialty Medicines Companies (ASMC), an informal working group of mid-market and smaller innovator pharmaceutical companies, today expressed concerns about H.R. 3962, the "Affordable Health Care for America Act," introduced by House Democrats last Thursday. These smaller companies fear that the cumulative effect of a host of provisions in H.R. 3962 will hinder their efforts to bring new medicines to market.

From required rebates to mandated discounts to new regulations, H.R. 3962 repeatedly raises new barriers for small companies seeking to fund life-saving research. Unlike larger companies, smaller companies typically must use cash generated from the sale of their own products for research. Unfortunately, the bill starves them of those necessary revenues. Its new burdens will damage the viability of small companies, and ultimately, put at risk the health of future patients who need medicines that smaller companies are more likely to develop.

Smaller companies generate much of the innovation in the pharmaceutical industry. Their work ranges over the entire spectrum from drugs for some of the most common diseases like cancer and diabetes to those for smaller, underserved populations with rare diseases. Without smaller companies' investment in the research and development of breakthrough products, many patients would go without any effective treatment. In many cases, these very treatments contain costs by eliminating the need for more expensive care.

"Small pharmaceutical companies often bring needed specialty medications to market when no one else will. Unfortunately, H.R. 3962 would stifle that innovation and prevent those efforts. Ultimately, the patients who need these medicines will suffer most," said Steve Cannon, an attorney representing ASMC.

But the damage runs deeper. H.R. 3962 will cut off small drug companies' ability to bring drugs developed overseas to the U.S. market as well. Small companies frequently license U.S. rights to those drugs, conduct U.S. clinical trials on them, and seek U.S. approval of them. Much of that economic activity would stop under H.R. 3962 - hurting the U.S. economy, killing U.S. jobs, and depriving U.S. patients of needed drugs.

Despite our concerns, ASMC looks forward to continuing to work with Congress to produce health care legislation that will produce better care and better drugs for all Americans.

SOURCE America's Specialty Medicines Companies

SOURCE America's Specialty Medicines Companies
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
2. Statement From The National Conclave on HIV/AIDS Policy for Black Clergy
3. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
4. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
5. Statement of Andrea Kavanagh, Director, Pure Salmon Campaign, on the Science Sea Lice Study
6. Statement from the American Diabetes Association Related to ACCORD Trial Announcement
7. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
8. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
9. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
10. Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus
11. VA Statement on Smoking Cessation Research Program
Post Your Comments:
(Date:11/26/2015)... Research and Markets ( ) has announced the ... Type (Dressings, Therapy Devices, Active Wound Care), Application (Surgical ... Geography - Global Forecast to 2020" report to ... --> The purpose of this report is to ... advanced wound care market. It involves deep dive analysis ...
(Date:11/26/2015)... ) has ... Market by Type (Reagents & Kits, Analyzers), ... Diagnostic Labs), Application (Research, Clinical Diagnostics), and ... report to their offering. --> ... the "Radioimmunoassay Market by Type (Reagents ...
(Date:11/25/2015)... 25, 2015  The American Academy of Pediatrics ... and the March of Dimes cheered today,s signature ... Infants Act of 2015 (S.799), which takes ... born exposed to drugs, such as opioids, and ... all three organizations have worked together leading advocacy ...
Breaking Medicine Technology:
(Date:11/29/2015)... Ca (PRWEB) , ... November 29, 2015 , ... Khanna ... American Board of Ophthalmology on November 25th 2015. Peer Certification by the ... field of his specialty. Certification in Ophthalmology is first obtained after the completion of ...
(Date:11/29/2015)... ... November 29, 2015 , ... Effective immediately, every single IguanaMed scrub style will ... Friday Target is offering a “Buy One Scrub Set, Get the 2nd Scrub Set ... purchase IguanaMed at a discounted price. , IguanaMed’s mission is to outfit ...
(Date:11/28/2015)... ... ... Trying to relax on a couch can actually be uncomfortable, so an ... due to personal experience with a bad back," he said. , This easy-to-use, versatile ... as increases support. It also makes it easier to eat, do other activities and ...
(Date:11/27/2015)... ... ... According to an article published November 13th on, much ... revolved around the fact that proper dental care, both at-home and in the dental ... periodontal disease (more commonly referred to as gum disease) and diabetes. According to Dr. ...
(Date:11/27/2015)... NC (PRWEB) , ... November 27, 2015 , ... A ... effective ways to treat it. Surviving Mesothelioma has just posted the findings on ... at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were treated ...
Breaking Medicine News(10 mins):